Immunologic enhancement with intermittent interleukin-2 therapy
Patent 5419900 Issued on May 30, 1995. Estimated Expiration Date: 
May 19, 2013. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
May 19, 2013. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesThermosetting aromatic resin composition Uses of interleukin-2 Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds Patent #: 5026687 InventorsAssigneeApplicationNo. 063315 filed on 05/19/1993US Classes:424/85.2, Interleukin514/50, 2,4-diketone pyrimidine or derivative (e.g., uracil, etc.)514/885IMMUNE RESPONSE AFFECTING DRUGExaminersPrimary: Nucker, Christine M.Assistant: Krsek-Staples, Julie Attorney, Agent or FirmForeign Patent References
International ClassesA61K 038/20A01N 043/48 AbstractA method for activating a mammalian immune system entails a series of continuous IL-2 infusions that are effected intermittently over an extended period. For example, IL-2 can be administered continuously for a period that is on the order of 5 days in length, and successive infusions of this nature can be separated by a period of at least 4 weeks. Sustained beneficial effects, including elevated CD4 cell counts, restoration of lymphocyte function and an increase in the number of IL-2 receptors, are achieved with such intermittent IL-2 therapy, which can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha.Other References
| |
